| Ytd | -44.08% | |
| 1y | 19.44% |
| Open | 8.93 | Prev Close | 9.01 | Low | 8.48 | High | 9.20 | Mkt Cap | 15.32M |
| Vol | 31.44K | Avg Vol | 62.48K | EPS | -2.96 | P/E | N/A | Forward P/E | 0.52 |
| Beta | 0.94 | Short Ratio | 4.47 | Inst. Own | 7.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 9.99 | 200-d Avg | 14.86 | 1yr Est | 17.00 |
Palatin Technologies (NYSEAMERICAN:PTN) said it is prioritizing development of next-generation melan
Palatin Technologies, Inc. (PTN) Q4 2026 Earnings Call Transcript
Gainers Kodiak Sciences (NASDAQ:KOD) shares increased by 57.4% to $50.93 during Monday's pre-ma
U.S. stock futures fell as gold and silver prices slid, sending Gold Fields down 16% and other preci
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business UpdatePR NewswirePRINCETON,
Palatin Techs (NASDAQ:PTN) reported quarterly losses of $(1.11) per share. This is a 59.34 percent i
Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pa
Webuy Global shares jumped 15% premarket after H1 revenue nearly doubled to $14.31M and net loss nar
Gainers Greenland Mines (NASDAQ:GRML) stock rose 108.1% to $5.93 during Monday's pre-market ses
Gainers bioAffinity Technologies (NASDAQ:BIAF) shares rose 43.1% to $6.53 during Tuesday's regu
Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisition
PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a bio
Palatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcript
Palatin Techs (AMEX:PTN) reported quarterly losses of $(0.37) per share which beat the analyst conse
Advancing MC4R-based obesity programs for rare obesity disorders with a focus on improved tolerabili
Palatin Technologies (NYSEAMERICAN:PTN) executives highlighted recent financing activity, progress i
Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call Transcript
Palatin Techs (AMEX:PTN) reported quarterly losses of $(2.86) per share which missed the analyst con
Advancing differentiated MC4R-based obesity programs into clinical development Melanocortin-based ob
Laidlaw & Co. analyst Yale Jen initiates coverage on Palatin Techs (AMEX:PTN) with a Buy rati
Palatin Technologies shares rose in after-hours trading as Janus Henderson Group and its subsidiary
Palatin Technologies shares rose in after-hours trading as Janus Henderson Group and its subsidiary
Pre-Market Stock Futures: The futures are trading higher on Wednesday after a stellar day across Wal
Palatin Technologies, Inc. (OTC:PTN) Q1 2026 Earnings Call November 13, 2025 11:00 AM EST Company Pa
Palatin Techs (AMEX:PTN) reported quarterly earnings of $4.26 per share. This is a 1192.31 percent i
Significant progress on multiple fronts – obesity pipeline advancing towards the clinic, out-licensi
Trading of Palatin's common shares resumed trading on NYSE today, November 12, 2025, under the symbo
Oral MC4R agonist PL7737 demonstrated robust weight loss, safety, and high oral bioavailability in p
$15.8 million at closing with up to an additional $15.8 million upon the cash exercise of the milest
Collaboration focused on developing potential first-in-class melanocortin receptor targeted treatmen
Boehringer and Palatin Technologies team up to develop potential first-in-class melanocortin recepto
Abivax shares jump as obefazimod meets key Phase 3 trial endpoints in ulcerative colitis with strong
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarter
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earning
Shares of Getaround, Inc. (NYSE: GETR) rose sharply in pre-market trading after the company report
Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $